Corey J. Langer, MD : Episode 10

Role of Gefitinib in EGRF-Mutant NSCLC

Video

Related Videos
George R. Simon, MD, FACP, FCCP
Ashish Saxena, MD, PhD
Eric Vallieres, MD, FRCSC
Benjamin Levy, MD
Francesco Di Meo, PhD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.